Regina received a PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. She then continued in academia for eight years.
During this time she worked at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. In 1997 she became Associate Professor at the University of Göteborg.
Regina has a broad scientific background in human and animal physiology, particularly in cardiovascular physiology. She has published over 40 papers and several review articles and book chapters within the field. She has detailed knowledge in the area of atherosclerosis and cardiovascular physiology – including human disease pathophysiological mechanisms, medical need, current treatment and related pre-clinical science and capabilities.
During her sixteen years at AstraZeneca, Regina has worked in drug projects and been in project leader roles for drug projects from target discovery up to Phase 2 in clinical development, in addition to her line management responsibilities.
In January 2011, Regina was appointed Senior Director and strategy area lead for atherosclerotic cardiovascular disease and she was instrumental in establishing the Cardiac Regeneration research area focusing on heart failure. Regina also led the IMED Biotech Unit’s first mRNA programme, VEGF-A from start to Phase 2 clinical development. In 2014, Regina was appointed Head of Bioscience Department Heart Failure Department with overall accountability to initiate and progress the portfolio in the cardiovascular and heart failure area.
In 2017, she was promoted to Vice President and Head of Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D.
Searching for a cure for heart failure
Senior Director and strategic area leader for cardiac regeneration, 2013
Senior Director and strategic area leader for Atherosclerotic Cardiovascular Disease, 2010
PRESENTER AND PANELIST
Presenter and Panelist at the mRNA health conference Boston, 2014
Imaging of atherosclerosis using non-invasive ultrasound
Imaging of Atherosclerosis in WHHL rabbits using non-invasive ultrasound. Wetterholm R, Caidahl K, Volkmann R, Brandt-Eliasson U, Fritsche-Danielson R, Gan LM. Ultrasound Med Biol. 2007: 33(5):720-6
Non-invasive real-time imaging of atherosclerosis
Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. Gan, L-M., Grönros, J., Hägg, U., Wikström, J. Theodoropoulos, C, and Fritsche-Danielson R. Atherosclerosis 2007: 190(2):313-320.
Effect of metalloproteinase inhibition on atherosclerotic plaque stability
Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Johnson, J L., Fritsche-Danielson, R., Behrendt, M. Westin- Eriksson, A., Wennbo, H., Herslöf, H., Elebring, M., George, S., McPheat, W. and Jackson, C L. Cardiovascular Research 2006: 71(3):586-595.
Role of ADAMTS-1 in Atherosclerosis
Role of ADAMTS-1 in Atherosclerosis: Remodeling of Carotid Artery, Immunohistochemistry, and Proteolysis of Versican. Jönsson-Rylander, A-C, Nilsson T., Fritsche-Danielson R, Hammarström A, Behrendt M, AnderssonJ-O, Lindgren K, Andersson A-K, Wallbrandt P, Brodin P, Thelin A, Westin a, Hurt-Camejo E, Lee-Søgaard C-H. Arteriosclerosis, Thrombosis & Vascular Biology 2005: 25(1):180-5.
We got some recent data on primary human cardiac progenitor-like cells, where we could actually show that these cells could proliferate and we are now characterizing these cells and studying if they can be differentiated into cardiomyocytes, endothelial cells and vascular smooth muscle cells.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.